Clinical Trial Update: A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of TAK-659 in combination with nivolumab in advanced solid tumors was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Carcinoma
• Solid Tumors
• Triple-negative Breast Cancer

Drugs mentioned

• TAK-659 (TAK-659)
• nivolumab (nivolumab)

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Triple-Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: TERMINATED | Results posted: 2020-03-31